- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02502526
Comparison of Centurion® Vision System With Balanced Tip and the Infiniti® Vision System With the Mini Flared Kelman (MFK) Tip During Cataract Extraction Surgery of Hard Lenses
May 31, 2018 updated by: Alcon Research
Comparison of Cumulative Dissipated Energy (CDE) and Balanced Salt Solution (BSS) Fluid Used With the Centurion® With the 45° Degree Balanced Ultrasound (U/S) Tip vs the Centurion® With Mini Flared Kelman U/S Tip vs the Infiniti® With Mini Flared Kelman U/S Tip on Hard Lenses
The purpose of this study is to demonstrate that the Centurion® Vision System (CVS) used with the 45° Balanced Tip will result in less Cumulative Dissipated Energy (CDE) than the lnfiniti® Vision System (IVS) used with the 45° Mini-Flared Kelman (MFK) tip during cataract extraction surgery via phacoemulsification of cataract grades NII- NIV [Lens opacities classification system II (LOCSII)].
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
231
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Willing and able to consent for participation;
- Willing and able to attend postoperative examinations per protocol schedule;
- Cataract in at least one eye with a Nuclear Opalescence of II-IV (via LOCSII) followed by posterior chamber intraocular lens (IOL) implantation;
- Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
- Planned multiple procedures, including Laser Phaco, LASIK, LRI's etc. during surgery or the course of this study;
- Severe conditions of acute or chronic diseases or illnesses that would increase the operative risk or confound the result of this investigation;
- Untreated or uncontrolled Glaucoma;
- Previous intraocular or corneal surgery of any kind, including any type of surgery for either refractive or therapeutic purposes;
- Poorly dilating pupil or other pupil defect;
- Current or previous use of an alpha-1-selective adrenoceptor blocking agent or antagonist of alpha 1A adrenoceptor (eg, Flomax®, Hyntrin®, or Cardura®);
- Severe retinal disorders;
- Corneal disease or retinal detachment;
- Other protocol-specified exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CVS with 45° Balanced Tip
Centurion® Vision System, 45° Balanced Tip used with INTREPID® Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
|
Other Names:
|
Active Comparator: CVS with 45° MFK Tip
Centurion® Vision System, 45° MFK Tip used with INTREPID® Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
|
Other Names:
|
Active Comparator: IVS with 45° MFK Tip
lnfiniti® Vision System, 45° MFK Tip used with Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative Dissipated Energy (CDE)
Time Frame: Day 0 (operative day)
|
Cumulative Dissipated Energy (CDE) represents the energy dissipated of the u/s tip and infusion sleeve at the incision point (5.6mm back from the cutting edge of the tip) during the removal of cataractous lens.
CDE was reported on the Vision System interface and measured in percent-seconds.
A lower CDE indicates that less energy was present at the incision site.
Only one eye (study eye) contributed to the analysis.
This outcome measure was pre-specified for CVS Bal and IVS MFK.
|
Day 0 (operative day)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative Dissipated Energy (CDE)
Time Frame: Day 0 (operative day)
|
Cumulative Dissipated Energy (CDE) represents the energy dissipated of the u/s tip and infusion sleeve at the incision point (5.6mm back from the cutting edge of the tip) during the removal of cataractous lens.
CDE was reported on the Vision System interface and measured in percent-seconds.
A lower CDE indicates that less energy was present at the incision site.
Only one eye (study eye) contributed to the analysis.
|
Day 0 (operative day)
|
Balanced Salt Solution (BSS) Fluid Used
Time Frame: Day 0 (operative day)
|
BSS Fluid was measured by weighing the BSS bag after priming.
BSS Used is Incision Leakage Fluid plus Aspiration Fluid Used.
A reduction in BSS fluid used implies less induced trauma to tissues.
Only one eye (study eye) contributed to the analysis.
|
Day 0 (operative day)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Alcon, A Novartis Division, Alcon, A Novartis Division
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 27, 2015
Primary Completion (Actual)
March 23, 2017
Study Completion (Actual)
November 30, 2017
Study Registration Dates
First Submitted
July 13, 2015
First Submitted That Met QC Criteria
July 16, 2015
First Posted (Estimate)
July 20, 2015
Study Record Updates
Last Update Posted (Actual)
July 2, 2018
Last Update Submitted That Met QC Criteria
May 31, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTU424-P001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cataracts
-
Johnson & Johnson Surgical Vision, Inc.Active, not recruiting
-
Johnson & Johnson Surgical Vision, Inc.Active, not recruiting
-
Johnson & Johnson Surgical Vision, Inc.Active, not recruitingCataractsUnited States
-
Johnson & Johnson Surgical Vision, Inc.Completed
-
Medical University of South CarolinaTerminated
-
Alcon ResearchCompleted
-
Alcon ResearchCompleted
-
Alcon ResearchCompleted
-
Medical University of ViennaCompleted
-
Prim. Prof. Dr. Oliver Findl, MBACompleted
Clinical Trials on Centurion® Vision System, 45° Balanced Tip
-
Alcon ResearchCompleted
-
Alcon ResearchCompleted
-
Optimal Acuity CorporationBochner Eye InstituteNot yet recruitingAge-related Macular DegenerationCanada
-
Kyungpook National University HospitalCompletedPhacoemulsificationKorea, Republic of
-
Centre Hospitalier Universitaire de NīmesUniversity Hospital, LimogesRecruitingColorectal Cancer | Adenoma | Intestinal PolypsFrance
-
Abbott Medical DevicesCompletedMyocardial Ischemia | Coronary Artery Disease | Vascular Disease | Coronary Artery Stenosis | EverolimusNetherlands, Germany, Denmark
-
Duke UniversityTerminatedColorectal Surgery | Goal-oriented Fluid TherapyKorea, Republic of
-
AllerganMAP Pharmaceuticals, Inc., a wholly owned subsidiary of AllerganCompletedHealthy SubjectsUnited Kingdom
-
University of CambridgeMedical Research CouncilCompletedDyspepsia | Barrett's Esophagus
-
AllerganMAP Pharmaceuticals, Inc., a wholly owned subsidiary of AllerganCompleted